David A. Siegel Aclaris Therapeutics, Inc. Transaction History
Two Sigma Advisers, LP
- $43.8 Billion
- Q2 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Aclaris Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 1,436,900 shares of ACRS stock, worth $1.62 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,436,900
Previous 1,451,100
0.98%
Holding current value
$1.62 Million
Previous $1.8 Million
12.17%
% of portfolio
0.0%
Previous 0.0%
Shares
17 transactions
Others Institutions Holding ACRS
# of Institutions
100Shares Held
52.2MCall Options Held
32.4KPut Options Held
3.3K-
Bml Capital Management, LLC Zionsville, IN13MShares$14.7 Million10.2% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.69MShares$5.3 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny3.34MShares$3.77 Million0.0% of portfolio
-
D. E. Shaw & Co., Inc. New York, NY3.32MShares$3.75 Million0.0% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD2.75MShares$3.11 Million0.09% of portfolio
About Aclaris Therapeutics, Inc.
- Ticker ACRS
- Exchange NASDAQ
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 66,671,800
- Market Cap $75.3M
- Description
- Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant ...